ADMA Stock Analysis: Buy, Sell, or Hold?
ADMA - ADMA Biologics, Inc.
$8.75
0.03 (0.40%)
▲
5d:
-2.51%
30d:
+3.86%
90d:
-20.57%
BUY
MODERATE Confidence
Analysis Updated: Jul 20, 2026 12:00 AM ET
Earnings: Aug 05, 2026
15d
Smart Money Distribution
None View Scanner →
Strength: 6.1/10
Get Alerted When ADMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ADMA shows positive signals but monitor for confirmation. Market pricing in 10.6% decline. Moderate conviction.
💡 BUY OPPORTUNITY: ADMA shows positive signals but monitor for confirmation. Market pricing in 10.6% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$23.10
Based on 13.8% avg growth
INTRINSIC VALUE TODAY
$14.34
39.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ADMA is currently trading at $8.74, which is considered fair relative to its 30-day fair value range of $8.43 to $9.01. From a valuation perspective, the stock is trading at a discount (Forward PE: 8.8) compared to its historical average (12.4). Remarkably, the market is currently pricing in an annual earnings decline of 10.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ADMA is in a strong downtrend. The price is currently testing key support at $8.54. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $17.00 (+95.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ADMA is in a strong downtrend. The price is currently testing key support at $8.54. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $17.00 (+95.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$8.43 -
$9.01
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 95.2% below Wall St target ($17.00)
Trading Range Analysis
30-Day Trading Range
$8.43 -
$9.01
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$8.54
Resistance Level
$9.33
Current Trend
Strong Downtrend
Technical data as of
Jul 20, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.84
Wall Street Target
$17.00
(+95.2%)
Revenue Growth (YoY)
15.9%
Earnings Growth (YoY)
-52.8%
Profit Margin
32.4%
Valuation Discount vs History
-10.6% cheaper
PE vs Historical
8.8 vs 12.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-10.6%
(market-implied from PE analysis)
1-Year Target
$7.84
(-10%)
2-Year Target
$7.06
(-19%)
3-Year Target
$6.35
(-27%)
3-Yr Target (if PE normalizes)
(PE: 9→12)
$8.90
(+2%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.0, Growth: 23.6%)
$39.11
(+349%)
Base:
(SPY PE: 8.8, Growth: 23.6%)
$16.46
(+89%)
Bear:
(PE: 7.5, Growth: 23.6%)
$13.99
(+61%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (13x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 12.96 | Current EPS (TTM): $0.68
Bull Case
$14.04
(+61%)
Analyst growth 44.9%, PE expands to 14.3
Base Case
$12.76
(+47%)
Market implied 44.9%, PE stable at 13.0
Bear Case
$5.99
(-31%)
Severe decline -20.0%, PE contracts to 11.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.8 to 12.4
Stabilization Target:
$12.21
(+40.2%)
PE Expansion Potential:
+40.2%
Share & Embed Analysis
Last updated: July 20, 2026 2:23 PM ET
Data refreshes hourly during market hours. Next update: 3:23 PM
Data refreshes hourly during market hours. Next update: 3:23 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADMA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
1
Sells
0
Net
INSIDERS SELLING
Recent Transactions
Kaitlin M Kestenberg-Mes…
SELL
10096 shares
2026-03-09
Steve Elms
BUY
7000 shares
2026-03-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 52 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1054 | 55 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$56 | 48 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$125 | 60 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
Advanced ADMA Option Strategies
Professional options setups generated by AI based on today's ADMA price and gamma walls.
